Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hysan nasal ointment is a topical nasal preparation developed by URSAPHARM Arzneimittel GmbH for the care and protection of the nasal mucosa. Its active ingredient is retinol palmitate (Vitamin A), which promotes the regeneration of epithelial tissues and maintains mucosal integrity. The ointment is formulated without preservatives and includes excipients such as paraffin and wax to create a protective film that moisturizes the nasal lining, relieves dryness, and facilitates the removal of scabs and crusts. It is primarily indicated for patients with chronic rhinitis and acute sinusitis, as demonstrated in clinical evaluations like the HYNASA-2018 trial in Germany.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on retinol palmitate.